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Should India launch a national immunisation programme against 
rotavirus? Yes
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The World Health Organization recommends inclusion of rotavirus vaccination of infants 
into all national immunisation programmes, with a strong recommendation for introduction 
of vaccine in countries like India where diarrhoeal deaths account for ≥10% of child 
mortality.1 The health burden of rotavirus in India is well established. WHO estimated that 
98 621 Indian children died from rotavirus gastroenteritis in 2008, representing about one 
third of deaths from diarrhoeal disease and 4% of all child deaths in India.2 More recent data 
from the Million Death Study, a nationally representative survey of 1.1 million Indian 
households, estimated that the virus causes 113 000 deaths a year.3 Both of these figures are 
conservative compared with an estimate of 147 000 annual rotavirus deaths obtained by 
directly extrapolating rates of laboratory confirmed rotavirus mortality from a contemporary 
community based birth cohort study in India.4
Non-fatal rotavirus gastroenteritis results in around 880 000 hospital admissions and 1.26 
million clinic visits annually in Indian children, costing $65m (358 crore; £41m; €51m).5 
Because rotavirus affects essentially all children in both developing and industrialised 
countries by the age of 5 years, interventions to improve hygiene and provide clean water 
alone are considered inadequate to prevent transmission. In addition, although severe and 
fatal outcomes of rotavirus diarrhoea can be reduced by timely access to medical treatment, 
a national survey in 2005–6 found that a quarter of Indian children under 5 years with 
diarrhoea received no treatment and only 39% received oral rehydration therapy.6 
Vaccination is therefore the best method to prevent deaths and morbidity.
Efficacious vaccines with favourable benefit:risk ratio
Two internationally licensed rotavirus vaccines have shown 85%–98% efficacy against 
severe rotavirus disease in large clinical trials in middle and high income countries 78 and 
their routine use has led to notable reductions in severe morbidity and mortality from 
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childhood diarrhoea.910 Neither vaccine has been tested for efficacy in India. Concerns 
about local efficacy have been raised, especially given the large diversity of rotavirus strains 
prevalent in India. However, pre-licensing and post-licensing data from diverse settings 
indicate that both vaccines provide good protection against a range of strains (including 
vaccine mismatch strains).911 The efficacy of the vaccines in India is likely to be similar to 
that in low income countries in Africa and Asia (40%–60%, including 42.7% in 
Bangladesh).12 Although this efficacy may seem low, the absolute public health benefits of 
vaccination are likely to be substantial because of the large health burden of rotavirus 
disease. With coverage similar to the first two doses of diphtheria-tetanus-pertussis (DTP) 
vaccine (73% and 63%, respectively), a 50% efficacious rotavirus vaccine would prevent 
around 44 000 deaths and 290 000 hospital admissions in Indian children each year.5
The benefits of rotavirus vaccination have to be weighed against possible risks. An earlier 
rotavirus vaccine was withdrawn in the United States in 1999 after it was linked to an 
increased risk of intussusception (about one case per 10 000 vaccinated infants).13 However, 
risk of intussusception was not increased in pivotal trials of both currently licensed rotavirus 
vaccines conducted in over 60 000 infants each.78 Post-licensing data have shown a small 
risk of intussusception, mainly in the first week after the first vaccine dose, in some high and 
middle countries but not in others.14 Data on intussusception risk from India or from other 
low income settings are lacking. Even if we assumed that the intussusception risk seen in 
some international settings (1–2 cases per 100 000 vaccinated infants) were to exist in India, 
the benefits of vaccination (around 44 000 rotavirus deaths prevented) would far exceed this 
risk. Similar benefit-risk considerations in other settings have led WHO and other policy 
bodies to continue support for use of rotavirus vaccines globally.14
Vaccines are cost effective and being locally developed
In a country where health spending is $54 per capita, cost effectiveness and affordability of 
vaccination are important considerations. Two separate analyses evaluated cost effectiveness 
of vaccination at prices ranging up to $7 per dose for a two dose schedule and showed that 
rotavirus vaccines could be considered very cost effective based on international standards, 
although substantial resources would be required to provide vaccine at the higher end of the 
price range.515 Currently, India has the opportunity to apply for financial support from the 
GAVI Alliance for procurement of rotavirus vaccines with a cofinancing requirement of 
$0.20 a dose.
Meanwhile, several Indian companies are manufacturing rotavirus vaccines, including an 
Indian neonatal rotavirus strain vaccine set to finish phase III testing in 2013.61314 If trial 
results are favourable, this vaccine could be licensed in India within two years. The 
manufacturer has pledged to provide vaccine at $1 per dose,16 which would make a 
vaccination programme highly cost effective. Furthermore, the potential availability of low 
cost, indigenously manufactured vaccines would allay concerns about long term 
sustainability of financial support from donors and would assure adequate vaccine supply.
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